Gene Disease Score gda Association Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 23314
Gene Symbol: SATB2
SATB2
Secondary malignant neoplasm of colon and/or rectum
0.010 AlteredExpression BEFREE In multivariable analysis, the SATB2 findings were independent of known clinicopathological prognostic markers, including <i>BRAF</i> mutation status.<b>Conclusion:</b> Patients with mCRC expressing high level of SATB2 have better prognosis and response to chemotherapy than those with low SATB2 expression. 31769323

2020

Entrez Id: 51251
Gene Symbol: NT5C3A
NT5C3A
Secondary malignant neoplasm of colon and/or rectum
0.010 Biomarker BEFREE A phase I study to determine the maximum tolerated dose of trifluridine/tipiracil and oxaliplatin in patients with refractory metastatic colorectal cancer: LUPIN study. 30838483

2020

Entrez Id: 6158
Gene Symbol: RPL28
RPL28
Secondary malignant neoplasm of colon and/or rectum
0.010 Biomarker BEFREE Our findings suggest that the ribosomal RPL28 protein may influence mCRC outcome. 31506518

2019

Entrez Id: 84634
Gene Symbol: KISS1R
KISS1R
Secondary malignant neoplasm of colon and/or rectum
0.010 AlteredExpression BEFREE KISS1 and KISS1R expression in primary and metastatic colorectal cancer. 30003725

2019

Entrez Id: 406892
Gene Symbol: MIR100
MIR100
Secondary malignant neoplasm of colon and/or rectum
0.010 GeneticVariation BEFREE MiR-218 and miR-100 polymorphisms as markers of irinotecan-based chemotherapy response in metastatic colorectal cancer. 31598748

2019

Entrez Id: 6139
Gene Symbol: RPL17
RPL17
Secondary malignant neoplasm of colon and/or rectum
0.010 Biomarker BEFREE However, the efficacy of PD-1-targeted therapy is poor in patients with microsatellite-stable (MSS) mCRC. 31788079

2019

Entrez Id: 2022
Gene Symbol: ENG
ENG
Secondary malignant neoplasm of colon and/or rectum
0.010 Biomarker BEFREE However, neither PAI-1 nor endoglin had prognostic significance in mCRC. 30880754

2019

Entrez Id: 59286
Gene Symbol: UBL5
UBL5
Secondary malignant neoplasm of colon and/or rectum
0.010 GeneticVariation BEFREE Binimetinib, encorafenib and cetuximab (BEACON Trial) combination therapy for patients with BRAF V600E-mutant metastatic colorectal cancer. 31840683

2019

Entrez Id: 406991
Gene Symbol: MIR21
MIR21
Secondary malignant neoplasm of colon and/or rectum
0.010 AlteredExpression BEFREE Mechanistically, miR-21-5p and miR-155-5p were transferred to colorectal cancer cells by MDE and bound to the BRG1 coding sequence, downregulating expression of BRG1, which has been identified as a key factor promoting the colorectal cancer metastasis, yet is downregulated in metastatic colorectal cancer cells. 30401711

2019

Entrez Id: 2023
Gene Symbol: ENO1
ENO1
Secondary malignant neoplasm of colon and/or rectum
0.010 Biomarker BEFREE To assess prognostic/predictive value of carcinoembryonic antigen (CEA), transthyretin (TRT), αenolase (NNE), β2-microglobulin (β2-micro), B-cell activating factor (BAFF) and circulating tumor cells (CTCs) in metastatic colorectal cancer (mCRC) patients treated with chemotherapy with or without bevacizumab. 28730771

2019

Entrez Id: 1493
Gene Symbol: CTLA4
CTLA4
Secondary malignant neoplasm of colon and/or rectum
0.010 Biomarker BEFREE Beside the small subgroup of deficient mismatch repair or microsatellite instable tumors (about 5%) as a surrogate for high mutational burden and subsequently high neoantigen load and immunogenicity, inhibitors of programmed death 1 (PD-1), programmed death ligand 1 (PD-L1) and/or cytotoxic T lymphocyte-associated antigen-4 were not or only modestly effective in metastatic colorectal cancer. 31413527

2019

Entrez Id: 56892
Gene Symbol: TCIM
TCIM
Secondary malignant neoplasm of colon and/or rectum
0.010 Biomarker BEFREE <b>Purpose</b>: The recent success of anti-PD1 antibody in metastatic colorectal cancer (CRC) patients with microsatellite instability (MSI), known to be associated with an upregulated Th1/Tc1 gene signature, provides new promising therapeutic strategies. 30906656

2019

Entrez Id: 10123
Gene Symbol: ARL4C
ARL4C
Secondary malignant neoplasm of colon and/or rectum
0.010 Biomarker BEFREE In addition, subcutaneous injection of ARL4C ASO was effective in reducing the growth of primary HCC and metastatic colorectal cancer in the liver of immunodeficient mice. 30647122

2019

Entrez Id: 23607
Gene Symbol: CD2AP
CD2AP
Secondary malignant neoplasm of colon and/or rectum
0.010 GeneticVariation BEFREE We successfully used this panel in the CMS classification of formalin-fixed paraffin-embedded (FFPE) tissues from mCRC cohorts, one of which is composed of paired primary tumors and metastases. 31004000

2019

Entrez Id: 563
Gene Symbol: AZGP1
AZGP1
Secondary malignant neoplasm of colon and/or rectum
0.010 Biomarker BEFREE Collectively, these results highlight AZGP1 as a new and promising therapeutic molecule for liver metastatic colorectal cancer. 31632499

2019

Entrez Id: 6947
Gene Symbol: TCN1
TCN1
Secondary malignant neoplasm of colon and/or rectum
0.010 Biomarker BEFREE <b>Purpose</b>: The recent success of anti-PD1 antibody in metastatic colorectal cancer (CRC) patients with microsatellite instability (MSI), known to be associated with an upregulated Th1/Tc1 gene signature, provides new promising therapeutic strategies. 30906656

2019

Entrez Id: 5473
Gene Symbol: PPBP
PPBP
Secondary malignant neoplasm of colon and/or rectum
0.010 Biomarker BEFREE <b>Purpose</b>: The recent success of anti-PD1 antibody in metastatic colorectal cancer (CRC) patients with microsatellite instability (MSI), known to be associated with an upregulated Th1/Tc1 gene signature, provides new promising therapeutic strategies. 30906656

2019

Entrez Id: 3814
Gene Symbol: KISS1
KISS1
Secondary malignant neoplasm of colon and/or rectum
0.010 AlteredExpression BEFREE KISS1 and KISS1R expression in primary and metastatic colorectal cancer. 30003725

2019

Entrez Id: 53373
Gene Symbol: TPCN1
TPCN1
Secondary malignant neoplasm of colon and/or rectum
0.010 Biomarker BEFREE Nicotinic Acid Adenine Dinucleotide Phosphate (NAADP) Induces Intracellular Ca<sup>2+</sup> Release through the Two-Pore Channel TPC1 in Metastatic Colorectal Cancer Cells. 30991693

2019

Entrez Id: 3485
Gene Symbol: IGFBP2
IGFBP2
Secondary malignant neoplasm of colon and/or rectum
0.010 Biomarker BEFREE Novel serum markers HSP60, CHI3L1, and IGFBP-2 in metastatic colorectal cancer. 31788106

2019

Entrez Id: 26136
Gene Symbol: TES
TES
Secondary malignant neoplasm of colon and/or rectum
0.010 Biomarker BEFREE Screening and Stepped Care Targeting Psychological Distress in Patients With Metastatic Colorectal Cancer: The TES Cluster Randomized Trial. 31390590

2019

Entrez Id: 9825
Gene Symbol: SPATA2
SPATA2
Secondary malignant neoplasm of colon and/or rectum
0.010 Biomarker BEFREE However, the efficacy of PD-1-targeted therapy is poor in patients with microsatellite-stable (MSS) mCRC. 31788079

2019

Entrez Id: 4739
Gene Symbol: NEDD9
NEDD9
Secondary malignant neoplasm of colon and/or rectum
0.010 AlteredExpression BEFREE E-cadherin and NEDD9 expression in primary colorectal cancer, metastatic lymph nodes and liver metastases. 30854064

2019

Entrez Id: 6597
Gene Symbol: SMARCA4
SMARCA4
Secondary malignant neoplasm of colon and/or rectum
0.010 AlteredExpression BEFREE Mechanistically, miR-21-5p and miR-155-5p were transferred to colorectal cancer cells by MDE and bound to the BRG1 coding sequence, downregulating expression of BRG1, which has been identified as a key factor promoting the colorectal cancer metastasis, yet is downregulated in metastatic colorectal cancer cells. 30401711

2019

Entrez Id: 100526842
Gene Symbol: RPL17-C18orf32
RPL17-C18orf32
Secondary malignant neoplasm of colon and/or rectum
0.010 Biomarker BEFREE However, the efficacy of PD-1-targeted therapy is poor in patients with microsatellite-stable (MSS) mCRC. 31788079

2019